You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


MHRA authorises UCB’s Bimzelx via post-Brexit licensing pathway

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved UCB’s Bimzelx (bimekizumab) for the treatment of adults with moderate to severe plaque psoriasis.